SCHEMBL25877356

SCHEMBL25877356

COc1cc(C=O)c(F)c(OCc2ccccc2)c1C

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERN1 O75460 3/20 0.49
ALDH1A1 P00352 3/20 0.46
MAPT P10636 2/20 0.46
L3MBTL1 Q9Y468 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
LMNA P02545 1/20 0.46
HPGD P15428 1/20 0.46
BCHE P06276 2/20 0.42
TUBB1 Q9H4B7 1/20 0.42
MAPK1 P28482 2/20 0.41
TDP1 Q9NUW8 1/20 0.41
MRGPRX4 Q96LA9 1/20 0.41
HTR1A P08908 1/20 0.40
ADRA1D P25100 1/20 0.40
ADRA1A P35348 1/20 0.40
ADRA1B P35368 1/20 0.40
KDM4E B2RXH2 1/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25877750 0.90 ERN1 (0.49) ERN1ALDH1A1MAPTL3MBTL1SMN1; SMN2
SCHEMBL24140597 0.90 ERN1 (0.51) ERN1ALDH1A1MAPTL3MBTL1SMN1; SMN2
SCHEMBL25877366 0.88 ERN1 (0.50) ERN1ALDH1A1MAPTL3MBTL1SMN1; SMN2
SCHEMBL25877469 0.85 PTPN1 (0.45) ERN1MAPTL3MBTL1SMN1; SMN2LMNA
SCHEMBL25877360 0.85 MAPT (0.52) ERN1ALDH1A1MAPTL3MBTL1SMN1; SMN2
SCHEMBL25877825 0.85 ERN1 (0.47) ERN1ALDH1A1MAPTL3MBTL1SMN1; SMN2
SCHEMBL25877824 0.84 ERN1 (0.47) ERN1ALDH1A1MAPTL3MBTL1SMN1; SMN2
SCHEMBL25877383 0.84 ERN1 (0.46) ERN1ALDH1A1MAPTL3MBTL1SMN1; SMN2
SCHEMBL5038227 0.83 ERN1 (0.52) ERN1ALDH1A1L3MBTL1BCHETUBB1
SCHEMBL24140500 0.83 ERN1 (0.50) ERN1ALDH1A1MAPTL3MBTL1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230234943-A1 TREX1 INHIBITORS AND USES THEREOF TEMPEST THERAPEUTICS, INC. 2023-07-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230234943-A1 TREX1 INHIBITORS AND USES THEREOF FEN1, ERCC4, DCLRE1B ERN1 258/4885ALDH1A1 1451/4885MAPT 3694/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.